A highly potent and selective PARP-inhibitor with IC50 values of 5 nM and 1 nM for PARP-1 and PARP-2, respectively.1 In a genetically engineered mouse model for BRCA1-associated breast cancer olaparib inhibited tumor growth and improved survival with no signs of toxicity.2 Synergizes with many other anticancer agents.3 Shows efficacy in colorectal cancers.4 Prevents house dust mite allergen-induced asthma in a mouse model.5
* VAT and and shipping costs not included. Errors and price changes excepted